Pulse Biosciences (NASDAQ:PLSE) Upgraded to “Sell” at StockNews.com

Pulse Biosciences (NASDAQ:PLSE) was upgraded by research analysts at StockNews.com to a “sell” rating in a note issued to investors on Tuesday.

Pulse Biosciences Stock Down 3.2 %

Shares of NASDAQ PLSE opened at $17.40 on Tuesday. The firm’s fifty day moving average is $17.93 and its 200 day moving average is $16.66. Pulse Biosciences has a 52 week low of $6.59 and a 52 week high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter in the previous year, the company earned ($0.19) EPS.

Insider Activity

In related news, Director Robert W. Duggan acquired 55,256 shares of the stock in a transaction on Friday, December 13th. The stock was acquired at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the completion of the acquisition, the director now directly owns 42,328,717 shares of the company’s stock, valued at approximately $727,207,358.06. This represents a 0.13 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Burke Thomas Barrett sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total value of $871,000.00. Following the transaction, the chief executive officer now owns 63,172 shares in the company, valued at $1,100,456.24. This trade represents a 44.18 % decrease in their position. The disclosure for this sale can be found here. Insiders own 71.50% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its holdings in Pulse Biosciences by 193.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after purchasing an additional 97,565 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Pulse Biosciences in the 3rd quarter worth about $588,000. Creative Planning lifted its position in Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after acquiring an additional 11,667 shares during the period. Quest Partners LLC bought a new stake in Pulse Biosciences during the second quarter worth about $91,000. Finally, Bank of New York Mellon Corp grew its holdings in Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock worth $570,000 after purchasing an additional 9,639 shares during the period. 76.95% of the stock is currently owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.